General Information of Drug (ID: DMLT1N3)

Drug Name
decavanadate Drug Info
Synonyms Decavanidate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5311062
TTD Drug ID
DMLT1N3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PIP2 DMOZV7N Discovery agent N.A. Investigative [2]
inositol 2,4,5-trisphosphate DM43G5Z Discovery agent N.A. Investigative [2]
xestospongin C DM4YQR2 Discovery agent N.A. Investigative [2]
Drug(s) Targeting P2X purinoceptor 7 (P2RX7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CE-224535 DMFCLT6 Arthralgia ME82 Phase 2/3 [7]
AZD9056 DMJGYPK Chronic obstructive pulmonary disease CA22 Phase 2 [8]
LY3857210 DMZO2V2 Pain MG30-MG3Z Phase 2 [9]
BIL010t DMV1EA9 Alzheimer disease 8A20 Phase 1/2 [10]
EVT 401 DMOG8IE Rheumatoid arthritis FA20 Phase 1 [11]
SGM-1019 DMDAHEL Inflammatory bowel disease DD72 Phase 1 [12]
GSK1482160 DMWDQOV Pain MG30-MG3Z Phase 1 [13]
JNJ-55308942 DM0QZJX Anhedonia MB24.2 Phase 1 [10]
JNJ-54175446 DMQ5ZVK Major depressive disorder 6A70.3 Phase 1 [14]
JNJ-479655 DMDU6GN Alzheimer disease 8A20 Clinical trial [15]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
inositol 2,4,5-trisphosphate DM43G5Z Discovery agent N.A. Investigative [3]
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [16]
PIP2 DMOZV7N Discovery agent N.A. Investigative [17]
adenosine diphosphate DMFUHKP N. A. N. A. Investigative [16]
BTP2 DMNM63G Discovery agent N.A. Investigative [18]
9-phenanthrol DMJFBQ1 Discovery agent N.A. Investigative [19]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
IP3 receptor isoform 1 (ITPR1) TT5HWAT ITPR1_HUMAN Antagonist [2]
IP3 receptor isoform 2 (IP3R2) TTK9OV3 ITPR2_HUMAN Antagonist [3]
IP3 receptor isoform 3 (ITPR3) TTH1769 ITPR3_HUMAN Antagonist [4]
Long transient receptor potential channel 4 (TRPM4) TTJ2HKA TRPM4_HUMAN Activator [5]
P2X purinoceptor 7 (P2RX7) TT473XN P2RX7_HUMAN Antagonist [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2459).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 744).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 745).
5 Decavanadate modulates gating of TRPM4 cation channels. J Physiol. 2004 Nov 1;560(Pt 3):753-65.
6 Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors. Eur J Pharmacol. 2006 Mar 18;534(1-3):19-29.
7 Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
8 Clinical pipeline report, company report or official report of AstraZeneca (2009).
9 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
10 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
11 Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.
16 Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5.
17 Phosphatidylinositol 4,5-bisphosphate rescues TRPM4 channels from desensitization. J Biol Chem. 2005 Nov 25;280(47):39185-92.
18 A pyrazole derivative potently inhibits lymphocyte Ca2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 ch... Mol Pharmacol. 2006 Apr;69(4):1413-20.
19 9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels. Br J Pharmacol. 2008 Apr;153(8):1697-705.